Literature DB >> 14654781

c-CBL is not required for leukemia induction by Bcr-Abl in mice.

Daniela M Dinulescu1, Lisa J Wood, Lei Shen, Marc Loriaux, Christopher L Corless, Alec W Gross, Ruibao Ren, Michael W N Deininger, Brian J Druker.   

Abstract

Bcr-Abl tyrosine kinase activity is essential for the pathogenesis of chronic myeloid leukemia (CML). A number of Bcr-Abl substrates have been identified, but it is not clear which of these substrates are required for Bcr-Abl to transform cells. The multifunctional protein c-Cbl is one of the most prominently tyrosine-phosphorylated proteins in Bcr-Abl-expressing cells. Using cell lines and mice with homozygous disruption of the c-CBL locus, we investigated the role of this protein for Bcr-Abl-driven transformation. We find that although c-Cbl(-/-) fibroblast cell lines show a deficit in Bcr-Abl transformation compared to wild-type (Wt) cells, this deficit was less pronounced in c-Cbl(-/-) B cells derived from murine bone marrow. Most importantly, in a transplantation model of CML, Bcr-Abl was capable of inducing fatal leukemia in mice in the absence of c-Cbl protein. Our results indicate that c-Cbl is dispensable for Bcr-Abl-induced leukemogenesis in mice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14654781     DOI: 10.1038/sj.onc.1206892

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia.

Authors:  Jian-Hua Mao; Xiao-Yan Sun; Jian-Xiang Liu; Qun-Ye Zhang; Ping Liu; Qiu-Hua Huang; Keqin Kathy Li; Quan Chen; Zhu Chen; Sai-Juan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-30       Impact factor: 11.205

2.  SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl.

Authors:  Jing Chen; Wen-Mei Yu; Hanako Daino; Hal E Broxmeyer; Brian J Druker; Cheng-Kui Qu
Journal:  Blood       Date:  2006-09-26       Impact factor: 22.113

3.  Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia.

Authors:  Stefania Trino; Luciana De Luca; Vittorio Simeon; Ilaria Laurenzana; Annalisa Morano; Antonella Caivano; Francesco La Rocca; Giuseppe Pietrantuono; Gabriella Bianchino; Vitina Grieco; Elisabetta Signorino; Alberto Fragasso; Maria Teresa Bochicchio; Claudia Venturi; Gianantonio Rosti; Giovanni Martinelli; Luigi Del Vecchio; Daniela Cilloni; Pellegrino Musto
Journal:  Tumour Biol       Date:  2015-07-21

Review 4.  FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.

Authors:  Zainab Jagani; Amrik Singh; Roya Khosravi-Far
Journal:  Biochim Biophys Acta       Date:  2007-10-16

Review 5.  Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.

Authors:  Michael W N Deininger
Journal:  J Cancer Res Clin Oncol       Date:  2003-11-07       Impact factor: 4.553

6.  SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function.

Authors:  N Hansen; H Ågerstam; M Wahlestedt; N Landberg; M Askmyr; M Ehinger; M Rissler; H Lilljebjörn; P Johnels; J Ishiko; J V Melo; W S Alexander; D Bryder; M Järås; T Fioretos
Journal:  Leukemia       Date:  2012-06-22       Impact factor: 11.528

7.  A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice.

Authors:  Kara J Johnson; Ian J Griswold; Thomas O'Hare; Amie S Corbin; Marc Loriaux; Michael W Deininger; Brian J Druker
Journal:  PLoS One       Date:  2009-10-13       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.